RxDoctor Payments Data

Andrew Anderson, OD

Optometrist · Mishawaka, INNPI 1104854942

Payments from drug & device makers

$3,027in general payments, 2019–2025

Across 90 payments — averaging $33.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$348
  • AbbVie$315
  • Bausch & Lomb Americas Inc.$292
  • Amgen$291
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$238
  • Biotissue Holdings Inc.$234
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$2,92997%
  • Education$983%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,027 in reported general payments places this provider in the 85th percentile of 1,318 optometrist providers in Indiana.

See all optometrist providers in Indiana

Medicare billing

Part B allowed, 2024
$61,133
Medicare patients
357
Services billed
710

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost31$14,713
XiidraLifitegrast11$12,964
SimbrinzaBrinzolamide/Brimonidine Tart22$5,741
Travoprost14$2,003
Latanoprost289$1,605
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat90$1,090
Prednisolone Acetate37$917
Brimonidine Tartrate84$847
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha55$609
Dorzolamide Hcl17$287
Ofloxacin16$142
Timolol Maleate33$108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$315$14,71331 claims
Bausch & Lomb Americas Inc.Xiidra$292$12,96411 claims
AlconSimbrinza$91$5,74122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,318 optometrist providers in Indiana.

Other optometrist in Mishawaka

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →